LDHC and cancer: The pan-cancer expression of LDHC/LDH-C4 based on TIMER (64) and UALCAN (65) suggests high levels in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), ovarian serous cystadenocarcinoma (OV), uveal melanoma (UVM), TGCTs, skin cutaneous melanoma (SKCM), HNSCC, and BC (Figures 2A, B).